Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study

By sjmartinez • July 19, 2023

Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, Chen Y, Rao N, Denis L, Gupta S. Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study. J Am Acad Dermatol. 2023 Aug;89(2):235-242. doi: 10.1016/j.jaad.2023.04.027. Epub 2023 Apr 23. PMID: 37094653.

Tags: Chronic Hand Eczema, Dermatology, Janus kinase inhibitor, modified total lesion-symptom score, Olive View DoM, Physician Global Assessment, Publications, Spleen Kinase Inhibitor

Dermatofibrosarcoma Protuberans of the Clavicular Skin in a 70-Year-Old Woman: Case Report and Management

Peng DS, Shen A, Kang Y, Yamamoto RK, Levins P. Dermatofibrosarcoma Protuberans of the Clavicular Skin in a 70-Year-Old Woman: Case Report and Management. Cureus.[...]

Helicobacter pylori as a risk factor for pemphigus and pemphigoid: A US large-scale cohort study using the TriNetX database

Kasperkiewicz M, Ludwig RJ, Curman P. Helicobacter pylori as a risk factor for pemphigus and pemphigoid: A US large-scale cohort study using the TriNetX database.[...]

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial

Ständer S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF. Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial. JAMA[...]